Publication:
Patterns of hydroxyurea prescription and use in routine clinical management of polycythemia vera: A multicenter chart review study

No Thumbnail Available

Date

2020-01-01

Authors

Ali, Rıdvan

Authors

Büyükaşık, Yahya
Turgut, Mehmet
Saydam, Güray
Yavuz, Selim
Ünal, Ali
Ar, Muhlis Cem
Ayyıldız, Orhan
Altuntaş, Fevzi
Okay, Mufide
Çiftçiler, Rafiye

Journal Title

Journal ISSN

Volume Title

Publisher

Galenos Yayincilik

Research Projects

Organizational Units

Journal Issue

Abstract

Objective: This study aimed to evaluate real-life data on patterns of hydroxyurea prescription/use in polycythemia vera (PV).Materials and Methods: This retrospective chart review study included PV patients who had received hydroxyurea therapy for at least 2 months after PV diagnosis. Data were collected from 10 representative academic medical centers.Results: Of 657 patients, 50.9% were in the high-risk group (age 60 years and/or history of thromboembolic event). The median duration of hydroxyurea therapy was 43.40 months for all patients; 70.2% of the patients had ongoing hydroxyurea therapy at last followup. Hydroxyurea was discontinued in 22.4% of the patients; the most common reason was death (38.5%). The predicted time until hydroxyurea discontinuation was 187.8 months (standard error: +/- 21.7) for all patients. This duration was shorter in females (140.3 +/- 37.7 vs. 187.8 +/- 29.7) (p=0.08). This trend was also observed in surviving patients aged >= 50 years at hydroxyurea initiation (122.2 +/- 12.4 vs. 187.8 +/- 30.7, p=0.03). Among the patients who were still on hydroxyurea therapy, 40.3% had a hematocrit concentration of >= 45% at their last followup visit, and the rate of patients with at least one elevated blood cell count was 67.8%.Conclusion: Hydroxyurea prescription patterns and treatment aims are frequently not in accordance with the guideline recommendations. Its discontinuation rate is higher in females.

Description

Keywords

Essential thrombocythemia, Prognostic value, Criteria, Hydroxycarbamide, Intolerance, Resistance, Survival, Events, Risk, Eln, Polycythemia vera, Hydroxyurea, Treatment outcome, Science & technology, Life sciences & biomedicine, Hematology

Citation

Collections

0

Views

0

Downloads

Search on Google Scholar